T. Cremona (Bern, Switzerland), A. Sverrild (København NV, Denmark)
Changes in forced oscillatory parameters in reversibility testing as predictors for cough variant asthma
T. Shirai (aShizuoka, Japan), H. Watanabe (aShizuoka, Japan), T. Akamatsu (aShizuoka, Japan), K. Tamura (aShizuoka, Japan), T. Masuda (aShizuoka, Japan), S. Takahashi (aShizuoka, Japan), Y. Tanaka (aShizuoka, Japan), Y. Endo (aShizuoka, Japan), T. Suzuki (aShizuoka, Japan), R. Noguchi (aShizuoka, Japan), M. Saigusa (aShizuoka, Japan), A. Yamamoto (aShizuoka, Japan), Y. Shishido (aShizuoka, Japan), T. Akita (aShizuoka, Japan), S. Morita (aShizuoka, Japan), K. Asada (aShizuoka, Japan)
|     |
Step-down of moderate-severe asthma treatment in clinical practice
A. Mogrovejo Calle (Valencia, Spain), E. Martínez Moragón (Valencia, Spain), J. Delgado Romero (Sevilla, Spain), A. Levy Naon (Ceuta, Spain), F. González Barcala (Ceuta, Spain), V. Serrano Gutiérrez (León, Spain), A. Moreno Fernández (Madrid, Spain)
| |
Effect of cumulative smoking history on disease burden and multimorbidity in adult-onset asthma
M. Tommola (Seinäjoki, Finland), P. Ilmarinen (Seinäjoki, Finland), L. Tuomisto (Seinäjoki, Finland), L. LehtimäKi (Tampere, Finland), O. Niemelä (Seinäjoki and Tampere, Finland), P. Nieminen (Oulu, Finland), H. Kankaanranta (Seinäjoki and Tampere, Finland)
| |
Exposure-response analysis of tezepelumab in patients with severe asthma to guide phase 3 dose selection
N. Ly (Mountain View, United States of America), Y. Zheng (Mountain View, United States of America), J. Griffiths (Gaithersburg, United States of America), R. Van Der Merwe (Cambridge, United Kingdom), B. Agoram (Mountain View, United States of America), L. Roskos (Gaithersburg, United States of America)
| |
Clustering analysis for omalizumab responder patient profiles identification. Fenoma study
C. Almonacid Sánchez (Madrid, Spain), J. Soto Campos (Jerez de la Frontera, Cádiz, Spain), P. Campo Mozo (Málaga, Spain), A. Moreira Jorge (Barcelona, Spain), I. Davila Gonzalez (Salamanca, Spain)
| |
Aerobic fitness in asthmatic adolescents with fixed airway obstruction
A. Sousa (São Paulo, Brazil), R. Silva (São Paulo, Brazil), A. Cabral (São Paulo, Brazil), J. Grindler (São Paulo, Brazil), A. Fonseca (São Paulo, Brazil), M. Martins (São Paulo, Brazil), C. Carvalho (São Paulo, Brazil)
| |
Can air purifier promote the indoor cleanliness and improve the patients with asthma?
T. Miyoshi (Tokyo, Japan), W. Furuie (Tokyo, Japan), Y. Otani (Tokyo, Japan), C. Tani (Tokyo, Japan), M. Waku (Tokyo, Japan), F. Koike (Tokyo, Japan), Y. Miyazaki (Tokyo, Japan), N. Inase (Tokyo, Japan), T. Sasano (Tokyo, Japan), M. Akaza (Tokyo, Japan), T. Kubota (Tokyo, Japan), Y. Sumi (Tokyo, Japan)
| |
Holistic management of asthma exacerbation in emergency department (ED): A-CARE (Asthma-COPD Afterhours Respiratory Nurse at Emergency) program
S. Chew (Singapore, Singapore), J. Leow (Singapore, Singapore), A. Chan (Singapore, Singapore), J. Chan (Singapore, Singapore), D. Tan (Singapore, Singapore), A. Butta (Singapore, Singapore), M. Koh (Singapore, Singapore)
| |
Antagonists for Chemoattractant receptor-homologous molecule expressed on Th2 cells in asthma: a meta-analysis and systematic review
J. Yang (Chengdu, China), J. Luo (Chengdu, China), L. Yang (Chengdu, China), D. Yang (Chengdu, China), D. Wang (Chengdu, China), B. Liu (Chengdu, China), B. Liang (Chengdu, China), C. Liu (Chengdu, China)
| |
A nocturnal temperature controlled laminar flow device (TLA) maintains good control of severe allergic asthma (SAA) after withdrawal of Omalizumab therapy
C. Wang (Taoyuan, Taiwan), C. Lo (Taoyuan, Taiwan), H. Kuo (Taoyuan, Taiwan)
| |
Consideration of Aspergillus component for Allergic Bronchopulmonary Aspergillosis(ABPA)
K. KUWABARA (NAGOYA, Japan), K. Takita (NAGOYA, Japan), R. Kondo (NAGOYA, Japan), T. Horiguchi (NAGOYA, Japan)
| |
Assessment of diagnostic accuracy of lung function indices and FeNO for a positive methacholine challenge in suspected asthmatics
N. Bougard (Liège, Belgium), F. Schleich (Liège, Belgium), F. Guissard (Liège, Belgium), R. Louis (Liège, Belgium)
| |
When omalizumab is effective, should treatment be for life?
M. Sanchez-Carpintero Abad (Madrid, Spain), V. Collados Arroyo (Madrid, Spain), G. Doblaré Higueras (Madrid, Spain), A. Henriquez Santana (Madrid, Spain), F. Ruiz Hornillos (Madrid, Spain), S. Blanco Bermejo (Madrid, Spain), F. Roig Vazquez (Madrid, Spain)
| |
Spanish study on unmet clinical needs in patients with uncontrolled severe asthma.
E. Martinez Moragon (Valencia, Spain), L. Perez De Llano (Luugo, Spain), B. Garcia-Cosio (Palma de Mallorca, Spain), V. Plaza (Barcelona, Spain)
| |
Development of a novel prediction model for acute asthma exacerbation
S. Park (Seoul, Republic of Korea), J. Kim (Seongnam, Republic of Korea), B. Seo (Incheon, Republic of Korea), W. Song (Seoul, Republic of Korea), H. Kwon (Seoul, Republic of Korea), T. Kim (Seoul, Republic of Korea), H. Moon (Seoul, Republic of Korea), Y. Cho (Seoul, Republic of Korea)
| |
impulse oscillometry in Small airway dysfunction in asthmatics and its utility in asthma control .
R. Sharshar (Tanta, Egypt)
| |
The validation of the Severe Asthma Questionnaire (SAQ).
M. Hyland (Plymouth, United Kingdom), R. Jones (Plymouth, United Kingdom), J. Lanario (Plymouth, United Kingdom), M. Masoli (Plymouth, United Kingdom)
| |